KR20210148110A - Jak2 저해제의 결정 형태 - Google Patents

Jak2 저해제의 결정 형태 Download PDF

Info

Publication number
KR20210148110A
KR20210148110A KR1020217029156A KR20217029156A KR20210148110A KR 20210148110 A KR20210148110 A KR 20210148110A KR 1020217029156 A KR1020217029156 A KR 1020217029156A KR 20217029156 A KR20217029156 A KR 20217029156A KR 20210148110 A KR20210148110 A KR 20210148110A
Authority
KR
South Korea
Prior art keywords
crystalline
crystalline form
compound
sample
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217029156A
Other languages
English (en)
Korean (ko)
Inventor
베노이트 로베르트
파스칼 빌롯
Original Assignee
임팩트 바이오메디신스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임팩트 바이오메디신스, 인코포레이티드 filed Critical 임팩트 바이오메디신스, 인코포레이티드
Publication of KR20210148110A publication Critical patent/KR20210148110A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217029156A 2019-02-12 2020-02-11 Jak2 저해제의 결정 형태 Ceased KR20210148110A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR1902018 2019-02-12
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Publications (1)

Publication Number Publication Date
KR20210148110A true KR20210148110A (ko) 2021-12-07

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029156A Ceased KR20210148110A (ko) 2019-02-12 2020-02-11 Jak2 저해제의 결정 형태

Country Status (13)

Country Link
US (1) US20220332706A1 (https=)
EP (1) EP3927704A4 (https=)
JP (2) JP2022520083A (https=)
KR (1) KR20210148110A (https=)
CN (1) CN114026088A (https=)
AU (1) AU2020221796A1 (https=)
BR (1) BR112021015318A2 (https=)
EA (1) EA202192237A1 (https=)
FR (1) FR3092581A1 (https=)
IL (1) IL285427A (https=)
MX (1) MX2021009423A (https=)
SG (1) SG11202108607QA (https=)
WO (1) WO2020167844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US12559463B2 (en) * 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
TW201316989A (zh) * 2011-07-21 2013-05-01 Sanofi Sa 用於治療真性多血症及原發性血小板過多症之組合物及方法
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Also Published As

Publication number Publication date
CN114026088A (zh) 2022-02-08
SG11202108607QA (en) 2021-09-29
JP2022520083A (ja) 2022-03-28
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
JP2025032217A (ja) 2025-03-11
FR3092581A1 (fr) 2020-08-14
MX2021009423A (es) 2021-11-17
AU2020221796A1 (en) 2021-08-12
IL285427A (en) 2021-09-30
EP3927704A4 (en) 2022-12-28
US20220332706A1 (en) 2022-10-20
EP3927704A1 (en) 2021-12-29
EA202192237A1 (ru) 2021-12-14

Similar Documents

Publication Publication Date Title
JP5289948B2 (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾール−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの結晶形態
CN113840604B (zh) Jak2抑制剂的结晶形式
JP2025032217A (ja) Ｊａｋ２阻害剤の結晶形態
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
KR20250130412A (ko) 화합물 a의 염과 결정형, 및 그 제조 방법과 용도
EP4438613A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
US20250101017A1 (en) Salt crystal form and free base crystal form of kinase inhibitor
JP2024163194A (ja) フロピリミジン化合物の酸付加塩の結晶形
US11466008B2 (en) Co-crystals of neflamapimod (VX-745)
US10544129B2 (en) Crystalline forms of AP26113, and preparation method thereof
CN108430987A (zh) Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
US20180244696A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor
CA2612459A1 (en) New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide
KR20250024987A (ko) 4-[(5-클로로피리딘-2-일)메톡시]-1-[3-(프로판-2-일)-1H,2H,3H,4H,5H-[1,4]디아제피노[1,7-a]인돌-9-일]-1,2-디하이드로피리딘-2-온의결정질 형태 및 이의 염, 이의 제조 방법 및 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601